RCT - Efficacy of Intravenous Vitamin C Versus Placebo on Estimated Blood Loss in Total Abdominal Hysterectomy (Vit C in TAH)

January 5, 2026 updated by: Aektanat Tawornkitpanich, Queen Savang Vadhana Memorial Hospital, Thailand

Efficacy of Intravenous Vitamin C Versus Placebo on Estimated Blood Loss in Total Abdominal Hysterectomy

Intervention Group: Received two 1 gm doses of Vitamin C intravenously (IV). first Dose: At midnight on the day of surgery. Second Dose: Immediately after the surgical incision. Control Group: Received two doses of a normal saline intravenously (IV) at the exact same times.

The primary outcome was to compare intraoperative blood loss between patients who received intravenous Vitamin C and those who did not, following an abdominal hysterectomy under general anesthesia.

Intraoperative estimated blood loss (EBL) was meticulously quantified by weighing surgical gauze and measuring suction canister volumes.

The secondary outcomes were to evaluate the potential benefits of Vitamin C administration, including:

  • Reduction in the decline of hematocrit levels after surgery.
  • Reduction of the length of hospital stay

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Thailand
    • Changwat Chon Buri
      • Si Racha, Changwat Chon Buri, Thailand, 20110
        • Queen Savang Vadhana Memorial Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Female patients who underwent total abdominal hysterectomy

    • No bleeding tendency.
    • No history of anticoagulant or thrombolytic drug use
    • No contraindications to vitamin C supplementation

Exclusion Criteria:

  • Inability to communicate in the Thai language.

    • Underwent total abdominal hysterectomy due to gynecologic malignancy.
    • Required emergency total abdominal hysterectomy.
    • History of vitamin C supplementation within 2 weeks prior to surgery.
    • History of smoking.
    • Previous abdominal surgery, such as bowel surgery, cesarean section

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Placebo
Dietary supplement: Vitamin C (Ascorbic Acid)

Received two 1 gm doses of Vitamin C intravenously (IV).

first Dose: At midnight on the day of surgery.

Second Dose: Immediately after the surgical incision.
Experimental: Experimental: Vitamin C
Intervention Group: Received two 1 gm doses of Vitamin C intravenously (IV). first Dose: At midnight on the day of surgery. Second Dose: Immediately after the surgical incision. Control Group: Received two doses of a normal saline intravenously (IV) at the exact same times.
Dietary supplement: Vitamin C (Ascorbic Acid)

Received two 1 gm doses of Vitamin C intravenously (IV).

first Dose: At midnight on the day of surgery.

Second Dose: Immediately after the surgical incision.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Intraoperative estimate blood loss
Time Frame: intraoperative
intraoperative

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Queen Savang Vadhana Memorial Hospital, Thailand

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2024

Primary Completion (Actual)

July 31, 2025

Study Completion (Estimated)

July 31, 2026

Study Registration Dates

First Submitted

January 5, 2026

First Submitted That Met QC Criteria

January 5, 2026

First Posted (Actual)

January 13, 2026

Study Record Updates

Last Update Posted (Actual)

January 13, 2026

Last Update Submitted That Met QC Criteria

January 5, 2026

Last Verified

September 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 012/2567

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Data was save in form of microsoft excel spreadsheet and SPSS file

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Myoma;Uterus

Clinical Trials on Vitamin C (Ascorbic Acid)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe